762 related articles for article (PubMed ID: 25375367)
1. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
Alphs L; Benson C; Cheshire-Kinney K; Lindenmayer JP; Mao L; Rodriguez SC; Starr HL
J Clin Psychiatry; 2015 May; 76(5):554-61. PubMed ID: 25938474
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS
JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035
[TBL] [Abstract][Full Text] [Related]
5. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia.
Alphs L; Mao L; Lynn Starr H; Benson C
Schizophr Res; 2016 Feb; 170(2-3):259-64. PubMed ID: 26742509
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
7. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
8. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
[TBL] [Abstract][Full Text] [Related]
9. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
[TBL] [Abstract][Full Text] [Related]
12. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
[TBL] [Abstract][Full Text] [Related]
13. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.
Alphs L; Bossie C; Mao L; Lee E; Starr HL
Early Interv Psychiatry; 2018 Feb; 12(1):55-65. PubMed ID: 26403322
[TBL] [Abstract][Full Text] [Related]
14. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
[TBL] [Abstract][Full Text] [Related]
15. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
Owen RT
Drugs Today (Barc); 2010 Jul; 46(7):463-71. PubMed ID: 20683501
[TBL] [Abstract][Full Text] [Related]
16. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
[TBL] [Abstract][Full Text] [Related]
17. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
20. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.
Perry R; Wolberg J; DiCrescento S
Am J Health Syst Pharm; 2012 Jan; 69(1):40-3. PubMed ID: 22180550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
